Beyond the threshold of standard supplementation. Engineering 6.4 mmol precision for elite human performance.
// ENCRYPTED_CHANNEL · NO_SPAM · UNSUBSCRIBE_ANYTIME
The 6.4 mmol threshold is the minimum concentration required to meaningfully activate the endothelial nitric oxide pathway. Below it — you are paying for expensive urine. The industry knows this. They ship under-dosed formulas because margins are higher and nobody audits them.
Vantix was engineered to cross that threshold — precisely, reproducibly, and with third-party verification on every batch.
Every molecule in Protocol 01 is selected to reinforce a specific stage of the aerobic energy pipeline — from oxygen delivery, through mitochondrial uptake, into measurable ATP output.
Nitric oxide precursors vasodilate endothelial tissue, increasing oxygen saturation toward the capillary bed.
Substrate shuttles (L-carnitine family) transport fatty acids across the inner mitochondrial membrane for oxidation.
Net result: sustained ATP throughput under load, measurable as time-to-exhaustion and recovery kinetics.
After years auditing longevity and performance products, the pattern was always the same: marketing-led dosing, zero verification, zero traceability. Vantix is the inverse. Every molecule is justified by literature. Every batch carries an ISO 17025 certificate. If a formulation can’t survive independent analysis — it doesn’t ship.
Protocol 01 is the first release. It is deliberately small, deliberately transparent, and deliberately engineered for operators who already measure.
Clinical-grade answers to the questions operators actually ask. No marketing. Data and pathway-level reasoning only.
Batch 001 is limited by design. Early access is granted in order of registration. No public sale at launch.
// POSITION_IN_QUEUE ASSIGNED AT CONFIRMATION
